Search Results - "Gracia Gil, Julia"

Biomarkers of response to ocrelizumab in relapsing–remitting multiple sclerosis by Rodríguez-Jorge, Fernando, Fernández-Velasco, José Ignacio, Villarrubia, Noelia, Gracia-Gil, Julia, Fernández, Eva, Meca-Lallana, Virginia, Díaz-Pérez, Carolina, Sainz de la Maza, Susana, Pacheco, Eva María, Quiroga, Ana, Ramió-Torrentà, Lluis, Martínez-Yélamos, Sergio, Bau, Laura, Monreal, Enric, López-Real, Ana, Rodero-Romero, Alexander, Borrega, Laura, Díaz, Santiago, Eguía, Pablo, Espiño, Mercedes, Chico-García, Juan Luis, Barrero, Francisco Javier, Martínez-Ginés, María Luisa, García-Domínguez, José Manuel, De la Fuente, Soraya, Moreno, Irene, Sainz-Amo, Raquel, Mañé-Martínez, M. Alba, Caminero, Ana, Castellanos, Fernando, Gómez López, Ana, Labiano-Fontcuberta, Andrés, Ayuso, Lucía, Abreu, Rossana, Hernández, Miguel Ángel, Meca-Lallana, José, Martín-Aguilar, Lorena, Muriel García, Alfonso, Masjuan, Jaime, Costa-Frossard, Lucienne, Villar, Luisa María

“…Objective To ascertain the changes of serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) values in relapsing–remitting multiple…”
Get full text

Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study by Oreja-Guevara, Celia, Meca-Lallana, José E., Díaz-Díaz, Judit, Ara, José-Ramón, Hernández Pérez, Miguel Ángel, Gracia Gil, Julia, Alonso Torres, Ana María, Pilo de la Fuente, Belén, Ramió-Torrentà, Lluís, Eichau Madueño, Sara, Gascón-Giménez, Francisco, Casanova, Bonaventura, Martínez-Yélamos, Sergio, Aguado Valcárcel, Marta, Martínez Ginés, Maria Luisa, El Berdei Montero, Yasmina, López Real, Ana María, González-Quintanilla, Vicente, De Torres, Laura, Martínez-Rodríguez, José Enrique, Costa-Frossard, Lucienne, Garcés Redondo, Moisés, Labiano Fontcuberta, Andrés, Castellanos-Pinedo, Fernando, García Merino, Juan Antonio, Muñoz Fernández, Carmen, Castillo-Triviño, Tamara, Meca-Lallana, Virginia, Peña Martínez, Joaquín, Rodríguez-Antigüedad, Alfredo, Prieto González, José María, Agüera Morales, Eduardo, Pérez Molina, Inmaculada, Solar Sánchez, Dulce M, Herrera Varo, Nicolás, Romero Sevilla, Raúl, Gómez Vicente, Lidia, Río, Jordi

“…•SPMS represents a considerable negative impact on patients’ HRQoL•Unfortunately, there is a lack of data about the impact of SPMS disability on HRQoL•DISCOVER…”
Get full text

Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population by Fernandez‐Diaz, Eva, Perez‐Vicente, Jose A., Villaverde‐Gonzalez, Ramon, Berenguer‐Ruiz, Leticia, Candeliere Merlicco, Antonio, Martinez‐Navarro, Maria Luisa, Gracia Gil, Julia, Romero‐Sanchez, Carlos M., Alfaro‐Saez, Arantxa, Diaz, Inmaculada, Gimenez‐Martinez, Juana, Mendez‐Miralles, Maria Angeles, Millan‐Pascual, Jorge, Jimenez‐Pancho, Javier, Mola, Santiago, Sempere, Angel P.

“…Objective Pivotal trial have shown that patients with multiple sclerosis (MS) receiving ocrelizumab had better outcomes. However, data on ocrelizumab in…”
Get full text

Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry by Romero-Sánchez, Carlos Manuel, Díaz-Maroto, Inmaculada, Fernández-Díaz, Eva, Sánchez-Larsen, Álvaro, Layos-Romero, Almudena, García-García, Jorge, González, Esther, Redondo-Peñas, Inmaculada, Perona-Moratalla, Ana Belén, Del Valle-Pérez, José Antonio, Gracia-Gil, Julia, Rojas-Bartolomé, Laura, Feria-Vilar, Inmaculada, Monteagudo, María, Palao, María, Palazón-García, Elena, Alcahut-Rodríguez, Cristian, Sopelana-Garay, David, Moreno, Yóscar, Ahmad, Javaad, Segura, Tomás

“…OBJECTIVEThe coronavirus disease 2019 (COVID-19) has spread worldwide since December 2019. Neurologic symptoms have been reported as part of the clinical…”
Get full text

COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab by Fernández-Díaz, Eva, Gracia-Gil, Julia, García-García, Jose Gregorio, Palao, María, Romero-Sánchez, Carlos M, Segura, Tomás

“…Alemtuzumab is a treatment for highly active multiple sclerosis (MS). Immunosuppression is considered a risk factor for SARS-CoV-2 infection and there is still…”
Get full text

High-Efficacy Disease-Modifying Therapies in People with Relapsing–Remitting Multiple Sclerosis: The Role of Risk Attitude in Treatment Decisions by Maurino, Jorge, Sotoca, Javier, Sempere, Ángel P., Brieva, Luis, López de Silanes, Carlos, Caminero, Ana B., Terzaghi, María, Gracia-Gil, Julia, Saposnik, Gustavo

“…Background Risk attitude is defined as the willingness to tolerate risk to achieve a greater expected return. Limited information is available on how…”
Get full text

Observational Study of Switching from Natalizumab to Immunomodulatory Drugs by Villaverde-González, Ramón, Gracia Gil, Julia, Pérez Sempere, Angel, Millán Pascual, Jorge, Marín Marín, José, Carcelén Gadea, María, Gabaldón Torres, Laura, Moreno Escribano, Antonio, Candeliere Merlicco, Antonio

“…To determine the effect of disease-modifying drugs (DMDs) on disease activity rebound in patients discontinuing natalizumab (NTZ). Twenty-one patients with…”
Get more information

COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab by Fernández-Díaz, Eva, Gracia-Gil, Julia, García-García, Jose Gregorio, Palao, María, Romero-Sánchez, Carlos M, Segura, Tomás

“…BACKGROUNDAlemtuzumab is a treatment for highly active multiple sclerosis (MS). Immunosuppression is considered a risk factor for SARS-CoV-2 infection and…”
Get full text

Administración de tratamiento trombolítico intravenoso en el ictus isquémico en fase aguda: resultados en el Complejo Hospitalario Universitario de Albacete by García García, Jorge, Gracia Gil, Julia, Sopelana Garay, David, Ayo Martín, Óscar, Vadillo Bermejo, Alfonso, Touza, Bernardo, Peñalver Pardines, Claudio, Zorita, Manuel D., Segura Martín, Tomás

Get full text